These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 38508571

  • 1. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.
    Wu Y, Hu L, Xie X, Li W, Wang Y, Zhang L, Huang P, Li F, Li J, Xia S, Yuan J, Li M, Wang Z, Zhang X.
    Am Heart J; 2024 Jul; 273():1-9. PubMed ID: 38508571
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
    Kuo HC, Guo MM, Lo MH, Hsieh KS, Huang YH.
    BMC Pediatr; 2018 Jun 22; 18(1):200. PubMed ID: 29933749
    [Abstract] [Full Text] [Related]

  • 3. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

  • 5. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
    Lin SY, He L, Xie LP, Wang Y, Lin YX, Cao YY, Yan WL, Liu F, Huang GY.
    Trials; 2021 Dec 11; 22(1):898. PubMed ID: 34895290
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
    Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 28; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
    Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators.
    N Engl J Med; 2007 Feb 15; 356(7):663-75. PubMed ID: 17301297
    [Abstract] [Full Text] [Related]

  • 9. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 15; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A, KAICA trial Investigators.
    Lancet; 2019 Mar 16; 393(10176):1128-1137. PubMed ID: 30853151
    [Abstract] [Full Text] [Related]

  • 11. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
    Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
    [Abstract] [Full Text] [Related]

  • 12. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
    Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A, KAICA Trial Investigators.
    BMJ Open; 2015 Dec 01; 5(12):e009562. PubMed ID: 26628527
    [Abstract] [Full Text] [Related]

  • 13. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
    Chiang MH, Liu HE, Wang JL.
    Arch Dis Child; 2021 Jul 01; 106(7):662-668. PubMed ID: 33172886
    [Abstract] [Full Text] [Related]

  • 14. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
    Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
    [Abstract] [Full Text] [Related]

  • 15. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm.
    Sanati F, Bagheri M, Eslami S, Khalooei A.
    Ann Pediatr Cardiol; 2021 May 17; 14(2):146-151. PubMed ID: 34103852
    [Abstract] [Full Text] [Related]

  • 17. Corticosteroids for the treatment of Kawasaki disease in children.
    Wardle AJ, Connolly GM, Seager MJ, Tulloh RM.
    Cochrane Database Syst Rev; 2017 Jan 27; 1(1):CD011188. PubMed ID: 28129459
    [Abstract] [Full Text] [Related]

  • 18. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
    Clin Exp Rheumatol; 2017 Jan 27; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [Abstract] [Full Text] [Related]

  • 19. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

  • 20. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT.
    Clin Pediatr (Phila); 2002 Oct 06; 41(8):597-601. PubMed ID: 12403377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.